TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06267183: A Phase I, Single-center, Randomized, Double-blind, Single-dose, Dose-ascending, Placebo-controlled Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 53 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT06267183 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06267183 Rescue Dossier →